Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,832 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.
Gleixner KV, Schneeweiss M, Eisenwort G, Berger D, Herrmann H, Blatt K, Greiner G, Byrgazov K, Hoermann G, Konopleva M, Waliul I, Cumaraswamy AA, Gunning PT, Maeda H, Moriggl R, Deininger M, Lion T, Andreeff M, Valent P. Gleixner KV, et al. Among authors: herrmann h. Haematologica. 2017 Sep;102(9):1519-1529. doi: 10.3324/haematol.2016.163436. Epub 2017 Jun 8. Haematologica. 2017. PMID: 28596283 Free PMC article.
The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils.
Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C, Lupinek C, Weghofer M, Bennett KL, Herrmann H, Schebesta A, Thomas WR, Vrtala S, Valenta R, Lee FY, Ellmeier W, Superti-Furga G, Valent P. Kneidinger M, et al. Among authors: herrmann h. Blood. 2008 Mar 15;111(6):3097-107. doi: 10.1182/blood-2007-08-104372. Epub 2008 Jan 7. Blood. 2008. PMID: 18180381 Free article.
Targeting of Hsp32 in solid tumors and leukemias: a novel approach to optimize anticancer therapy.
Gleixner KV, Mayerhofer M, Vales A, Gruze A, Hörmann G, Cerny-Reiterer S, Lackner E, Hadzijusufovic E, Herrmann H, Iyer AK, Krauth MT, Pickl WF, Marian B, Panzer-Grümayer R, Sillaber C, Maeda H, Zielinski C, Valent P. Gleixner KV, et al. Among authors: herrmann h. Curr Cancer Drug Targets. 2009 Aug;9(5):675-89. doi: 10.2174/156800909789057024. Epub 2009 Aug 1. Curr Cancer Drug Targets. 2009. PMID: 19508170
A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells.
Rix U, Remsing Rix LL, Terker AS, Fernbach NV, Hantschel O, Planyavsky M, Breitwieser FP, Herrmann H, Colinge J, Bennett KL, Augustin M, Till JH, Heinrich MC, Valent P, Superti-Furga G. Rix U, et al. Among authors: herrmann h. Leukemia. 2010 Jan;24(1):44-50. doi: 10.1038/leu.2009.228. Epub 2009 Nov 5. Leukemia. 2010. PMID: 19890374
Neoplastic stem cells: current concepts and clinical perspectives.
Schulenburg A, Brämswig K, Herrmann H, Karlic H, Mirkina I, Hubmann R, Laffer S, Marian B, Shehata M, Krepler C, Pehamberger H, Grunt T, Jäger U, Zielinski CC, Valent P. Schulenburg A, et al. Among authors: herrmann h. Crit Rev Oncol Hematol. 2010 Nov;76(2):79-98. doi: 10.1016/j.critrevonc.2010.01.001. Epub 2010 Feb 25. Crit Rev Oncol Hematol. 2010. PMID: 20185329 Review.
1,832 results